

Giuseppe Daniele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/623043/publications.pdf>

Version: 2024-02-01

64
papers

2,800
citations

279701

23
h-index

182361

51
g-index

67
all docs

67
docs citations

67
times ranked

4271
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report. <i>Frontiers in Endocrinology</i> , 2022, 13, 847778.	1.5	2
2	Effects of Intermittent Fasting on Brain Metabolism. <i>Nutrients</i> , 2022, 14, 1275.	1.7	17
3	Insulin secretion and action affect glucose variability in the early stages of glucose intolerance. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3531.	1.7	4
4	Brain effect of bariatric surgery in people with obesity. <i>International Journal of Obesity</i> , 2022, 46, 1671-1677.	1.6	11
5	Circulating N-Acetylaspartate does not track brain NAA concentrations, cognitive function or features of small vessel disease in humans. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
6	Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021, 114, 154416.	1.5	23
7	Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> 2020;43:e139–e141. <i>Diabetes Care</i> , 2021, 44, e81-e81.	4.3	1
8	Bariatric surgery restores visual cortical plasticity in nondiabetic subjects with obesity. <i>International Journal of Obesity</i> , 2021, 45, 1821-1829.	1.6	4
9	Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. <i>Nature Metabolism</i> , 2021, 3, 774-785.	5.1	259
10	Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 699477.	1.2	2
11	Effects of treatment with metformin and/or sitagliptin on beta cell function and insulin resistance in prediabetic women with previous gestational diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 648-657.	2.2	15
12	Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> , 2020, 43, e139-e141.	4.3	13
13	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. <i>Diabetologia</i> , 2020, 63, 2423-2433.	2.9	17
14	Plasma N-acetylaspartate: Development and validation of a quantitative assay based on HPLC-MS-MS and sample derivatization. <i>Clinica Chimica Acta</i> , 2020, 508, 146-153.	0.5	5
15	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. <i>Diabetes Care</i> , 2020, 43, 1065-1069.	4.3	15
16	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108112.	1.1	21
17	Nesidioblastosis and Insulinoma: A Rare Coexistence and a Therapeutic Challenge. <i>Frontiers in Endocrinology</i> , 2020, 11, 10.	1.5	11
18	Plasma N-Acetylaspartate Is Related to Age, Obesity, and Glucose Metabolism: Effects of Antidiabetic Treatment and Bariatric Surgery. <i>Frontiers in Endocrinology</i> , 2020, 11, 216.	1.5	10

#	ARTICLE	IF	CITATIONS
19	Exenatide modulates visual cortex responses. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3167.	1.7	3
20	Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. <i>Cardiovascular Diabetology</i> , 2019, 18, 159.	2.7	43
21	Altered Visual Plasticity in Morbidly Obese Subjects. <i>IScience</i> , 2019, 22, 206-213.	1.9	20
22	Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon <i>Papio hamadryas</i> . <i>JCI Insight</i> , 2019, 4, .	2.3	15
23	LA MALATTIA RENALE CRONICA NON-ALBUMINURICA NEL DIABETE MELLITO TIPO 1. <i>Il Diabete</i> , 2019, 31, .	0.0	0
24	Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 550-557.	1.2	14
25	Empagliflozin Treatment Is Associated With Improved β -Cell Function in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1402-1407.	1.8	63
26	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 1-44.	0.1	0
27	The potential role of the osteopontin-osteocalcin-osteoprotegerin triad in the pathogenesis of prediabetes in humans. <i>Acta Diabetologica</i> , 2018, 55, 139-148.	1.2	14
28	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 527-569.	0.1	0
29	Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2018, 17, 78.	2.7	5
30	Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. <i>Drugs</i> , 2017, 77, 247-264.	4.9	25
31	Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 809-813.	2.2	61
32	Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2017, 66, 1999-2006.	0.3	67
33	Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β -Cell Function in Subjects With Impaired Fasting Glucose. <i>Diabetes</i> , 2017, 66, 2495-2502.	0.3	21
34	Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. <i>Diabetologia</i> , 2017, 60, 1102-1113.	2.9	38
35	Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes. <i>FEBS Journal</i> , 2017, 284, 451-465.	2.2	27
36	Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter]. <i>Diabetologia</i> , 2017, 60, 2123-2125.	2.9	2

#	ARTICLE	IF	CITATIONS
37	Metabolic regulation of GLP-1 and PC1/3 in pancreatic $\hat{\pm}$ -cell line. PLoS ONE, 2017, 12, e0187836.	1.1	31
38	Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects. Diabetes Care, 2016, 39, 1804-1810.	4.3	15
39	Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 2036-2041.	4.3	155
40	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology, 2016, 64, 2028-2037.	3.6	78
41	Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1249-1256.	1.8	30
42	Access to emergency room for hypoglycaemia in people with diabetes. Diabetes/Metabolism Research and Reviews, 2015, 31, 745-751.	1.7	15
43	The impact of vitamin D deficiency on patients undergoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes. Endocrine, 2015, 50, 568-574.	1.1	19
44	Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. Diabetes, 2015, 64, 3406-3412.	0.3	45
45	Dapagliflozin Lowers Plasma Glucose Concentration and Improves $\hat{\beta}$ -Cell Function. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1927-1932.	1.8	133
46	Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism. Diabetes Care, 2015, 38, 1509-1517.	4.3	99
47	Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146TCF7L2Gene Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1160-E1167.	1.8	15
48	Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus. Acta Diabetologica, 2015, 52, 897-903.	1.2	1
49	GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetologica, 2015, 52, 1129-1133.	1.2	15
50	Fiber orientation measurements by diffusion tensor imaging improve hydrogen-1 magnetic resonance spectroscopy of intramyocellular lipids in human leg muscles. Journal of Medical Imaging, 2015, 2, 026002.	0.8	3
51	The inflammatory status score including IL-6, TNF- $\hat{\pm}$, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetologica, 2014, 51, 123-131.	1.2	211
52	What are the pharmacotherapy options for treating prediabetes?. Expert Opinion on Pharmacotherapy, 2014, 15, 2003-2018.	0.9	21
53	Chronic Reduction of Plasma Free Fatty Acid Improves Mitochondrial Function and Whole-Body Insulin Sensitivity in Obese and Type 2 Diabetic Individuals. Diabetes, 2014, 63, 2812-2820.	0.3	60
54	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. Journal of Clinical Investigation, 2014, 124, 509-514.	3.9	661

#	ARTICLE	IF	CITATIONS
55	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. <i>Journal of Clinical Investigation</i> , 2014, 124, 2287-2287.	3.9	4
56	Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3/TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. <i>Diabetologia</i> , 2013, 56, 2153-2163.	2.9	71
57	Ectopic fat: the true culprit linking obesity and cardiovascular disease?. <i>Thrombosis and Haemostasis</i> , 2013, 110, 651-660.	1.8	51
58	Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk. <i>Current Pharmaceutical Design</i> , 2013, 19, 2420-2431.	0.9	37
59	Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction. <i>Diabetologia</i> , 2012, 55, 1847-1855.	2.9	95
60	Serum gamma-glutamyltransferase levels are related to insulin sensitivity and secretion in subjects with abnormal glucose regulation. <i>Diabetes/Metabolism Research and Reviews</i> , 2010, 26, 181-186.	1.7	5
61	Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. <i>Diabetes Care</i> , 2009, 32, S342-S348.	4.3	27
62	Prognostic implications of diabetes phenotyping: new concepts for an old disease. <i>Internal and Emergency Medicine</i> , 2009, 4, 325-329.	1.0	0
63	Optimizing management of metabolic syndrome to reduce risk: focus on life-style. <i>Internal and Emergency Medicine</i> , 2008, 3, 87-98.	1.0	25
64	The metabolic syndrome is related to albuminuria in Type 2 diabetes. <i>Diabetic Medicine</i> , 2008, 25, 1412-1418.	1.2	22